Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?

Abstract Introduction Allergic comorbidities are common in patients with atopic dermatitis (AD). Individual trials with abrocitinib or dupilumab demonstrated efficacy and safety in patients with moderate-to-severe AD and allergic comorbidities. This post hoc analysis of the phase 3 JADE COMPARE and...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Eric L. Simpson, Jonathan I. Silverberg, Bob Geng, José-Manuel Carrascosa, Thomas Bieber, Patrick M. Brunner, Delphine Staumont-Sallé, Chao Ji, Pinaki Biswas, Claire Feeney, Irene Hernández-Martín, Francisco José Rebollo Laserna, Herwig Koppensteiner
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Adis, Springer Healthcare 2025-09-01
Serie:	Dermatology and Therapy
Soggetti:	Abrocitinib Allergic rhinitis Asthma Comorbidity Dupilumab Food allergy
Accesso online:	https://doi.org/10.1007/s13555-025-01516-w
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!